SGEN is a biotechnology company focused on the development and commercialization of innovative therapies for cancer treatment. The company specializes in antibody-drug conjugates (ADCs), which combine targeted antibodies with potent cytotoxic drugs to selectively destroy cancer cells while minimizing damage to healthy tissue. SGEN's portfolio includes several FDA-approved products and a robust pipeline of investigational therapies aimed at addressing various types of cancer. The company is committed to advancing cancer care through scientific innovation and collaboration.